ArticleCellular oncology (Dordrecht, Netherlands)2015
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Kristy J Gotink et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this papercites it